#GLP-1 receptor

[newsepick]

Semaglutide enhances cognitive abilities and reduces Alzheimer’s pathology in mice and human brain models

A study in *Biomedicine & Pharmacotherapy* explored the effects of Semaglutide on Alzheimer's Disease (AD) in mouse and human brain organoid models. Researchers found that Semaglutide improved cognitive function, reduced amyloid plaque and Tau protein levels, and decreased neuroinflammation in APP/PS1 mice. Behavioral tests indicated enhanced learning and memory, while biochemical assessments showed modulation of key neuroprotective pathways. Additionally, Semaglutide increased oxytocin levels in human models, suggesting its therapeutic potential through GLP-1 receptor and oxytocin interaction. These findings point to Semaglutide as a promising candidate in AD treatment, warranting further research.

[scientificinquirer-blog]

Expanding access to weight-loss drugs could save thousands of lives a year

 Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States, according to a new study led by researchers at Yale School of Public Health and the University of Florida. The findings highlight the critical need to remove existing barriers that are hindering people’s access to effective weight loss treatments and impeding…

[nfuzewellness]

Exploring Semaglutide and Trizeptride: Contrasting Weight Loss Injections

Discover the differences between Semaglutide and Trizeptride, two innovative GLP-1 receptor agonists for weight loss. Learn about their mechanisms, benefits, and which might be right for your obesity treatment needs in Edwardsville.

[shrinksinsneakers]

A recent study published in JAMA Network Open investigated the relationship between semaglutide, a medication commonly used for type 2 diabetes (T2D), and the risk of opioid overdose in patients with both T2D and opioid use disorder (OUD). 

[mehmetyildizmelbourne-blog]

Let's Talk About GLP-1 receptor agonists (GLP1-RAs)

GLP-1 receptor agonists (GLP1-RAs), including Tirzepatide and Semaglutide, are showing promise not just in managing type 2 diabetes but also in addressing inflammatory and neurodegenerative conditions. These medications have demonstrated benefits beyond blood sugar control, such as anti-inflammatory and neuroprotective effects. Research indicates that they may potentially aid in the treatment of…

[mitalipingale]

https://social.studentb.eu/read-blog/184594_glp-1-receptor-agonist-market-size-analysis-and-forecast-2031.html

The GLP-1 Receptor Agonist Market in 2023 is US$ 14.44 billion, and is expected to reach US$ 23.58 billion by 2031 at a CAGR of 6.32%.

[peptide-ltd]

How does Retatrutide Work when We Using it, how Magic!

Retatrutide works

Depending on which cell receptors they bind to, different receptor agonists play distinct roles in our bodies. Retatrutide, as previously stated, stimulates three receptor agonists: GLP-1, GIP, and glucagon. To gain a better grasp of retatrutide mechanism of action, you should first learn about receptor agonists. Here’s how each one works in our bodies and why they help with weight loss:

GLP-1 (Glucagon-like Peptide-1):

Glucagon-like peptide-1 (GLP-1) emerges as an intestinal peptide hormone that our body generates in response to meal consumption. This hormone assumes a versatile role, with its primary significance lying in the regulation of food intake and hunger sensations. As we partake in a meal or a snack, the elevation of our blood glucose levels triggers the release of GLP-1, setting in motion the stimulation of insulin secretion from the pancreas

Insulin, a pivotal hormone manufactured by our body, functions as the key to unlocking cellular entry for glucose originating from dietary intake. The cells’ reliance on glucose as their chief energy source for fundamental processes underscores the critical role of insulin. Its role extends to the meticulous management of blood sugar levels and its implications for weight management. The absence of sufficient insulin erects barriers to glucose ingress into cells, not only impeding nutrient absorption but also leading to escalated blood sugar levels. Consequently, surplus glucose metamorphoses into adipose tissue, contributing to weight gain.

GLP-1 orchestrates the promotion of insulin secretion from the pancreas while simultaneously orchestrating the curtailment of glucose release from the liver. Beyond its contributions to glucose moderation, GLP-1 orchestrates a deliberate deceleration of gastric emptying, inducing a protracted digestive journey. This translates to a hastened sense of satiety and contentment following meals. Furthermore, GLP-1 exercises its influence on the brain’s hunger center, instigating a reduction in the sensation of appetite. These dual facets of GLP-1’s influence work in concert to quell hunger, akin to the mechanisms of appetite suppressants like Phentermine, often employed to foster weight loss endeavors.

GIP (Glucose-Dependent Insulinotropic Polypeptide):

Just as GLP-1, glucose-dependent insulinotropic polypeptide (GIP) belongs to the family of incretin hormones. Hence, both these peptide hormones exhibit strikingly similar behaviors. This hormone is generated within the small intestine following a meal, where it homes in on the pancreatic beta cells, effectively triggering the discharge of insulin. This action contributes to the regulation of post-meal blood sugar levels. Nevertheless, GIP’s sojourn within our system is brief; it undergoes breakdown in approximately 7 minutes. GIP receptor agonist medications, exemplified by Mounjaro, are designed to sustain elevated GIP levels in our bloodstream, extending its presence. This hormone induces a gradual-paced gastric emptying process while concurrently curbing appetite. Its influence extends to both the brain and the digestive system. That is why the stomach is one of the best place to inject Tirzepatide for weight loss.

Glucagon receptor:

Glucagon, an additional hormone of paramount significance, assumes a pivotal role in the orchestration of blood sugar levels. Analogous to GLP-1 and GIP, its origin lies within the pancreas, although it emanates from a distinct variety of cells known as alpha cells. In stark contrast to the aforementioned hormones, glucagon operates in a manner diametrically opposed. When our blood sugar levels begin to ebb, prompted by factors such as fasting or slumber, glucagon initiates the conversion of glycogen—the reserved form of sugar—into glucose, thus providing our body with a readily accessible fuel source. Although insulin and glucagon wield divergent effects, they collaborate in tandem to uphold optimal sugar levels. Insulin channels sugar into glycogen, while glucagon undertakes the converse.

How does glucagon contribute to weight loss? Our system stockpiles surplus glucose from dietary intake as both glycogen and adipose tissue. During prolonged intervals devoid of carbohydrate consumption—during periods of sleep, adherence to a low-calorie regimen, or intermittent fasting, for instance—glucagon emerges as a vital player, endeavoring to engineer glucose generation. This process commences by dismantling glycogen reserves; once this reservoir is depleted, glucagon turns its focus to the disintegration of fat stores, converting them into a usable energy source.

[trendbuzzz]

6 Week Belly Ozempic Weight Loss Before and After

In a world where countless weight loss methods promise quick fixes, finding an approach that not only delivers results but also targets that stubborn belly fat can feel like an elusive quest. But what if we told you that a 6 Week Belly Ozempic Weight Loss Before and After challenge could be the key to your long-awaited transformation? Hold on tight because we are about to go on a journey that…

[myblogscmi]

Navigating The Future: Trends And Challenges In The GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market, a critical segment of the pharmaceutical industry, is poised for significant transformations as it continues to address the needs of patients with type 2 diabetes. This dynamic market has seen impressive growth and innovation, but it also faces unique challenges that warrant attention and proactive strategies. Combination Therapies: Combination therapies, involving the use of GLP-1 receptor agonists in conjunction with other diabetes medications, are becoming more common. This approach can provide synergistic effects and better blood sugar control, offering patients comprehensive treatment strategies.

Personalized Treatment: The concept of personalized medicine is gaining traction in the GLP-1 Receptor Agonist Market. Advances in genetics and molecular biology are enabling healthcare providers to tailor treatment plans to individual patients' needs, maximizing the effectiveness of these medications.

Digital Health Solutions: The integration of digital health solutions, such as mobile apps and wearable devices, is transforming how patients and healthcare professionals manage diabetes. These technologies can assist with medication adherence, track blood sugar levels, and provide real-time insights into patients' health status.

Affordability and Access: Despite the market's growth, affordability and access to GLP-1 receptor agonists remain challenges for many patients. Developing cost-effective options and collaborating with healthcare systems to improve access will be crucial to ensuring equitable treatment for all. Long-term Safety and Efficacy: While the cardiovascular benefits of GLP-1 receptor agonists are well-established, the long-term safety and efficacy of these medications require continuous monitoring. Post-market surveillance and research are essential to identify any potential adverse effects over extended periods.

Patient Education: Educating patients about the benefits, proper usage, and potential side effects of GLP-1 receptor agonists is vital. Empowering patients to make informed decisions about their treatment can improve adherence and overall treatment outcomes.

As the GLP-1 Receptor Agonist Market navigates the future, collaboration among pharmaceutical companies, healthcare providers, regulators, and patient advocacy groups will be instrumental. By working together, these stakeholders can overcome challenges and capitalize on emerging trends to improve the lives of individuals with type 2 diabetes.

In conclusion, the GLP-1 receptor agonist market's journey is one of growth, innovation, and adaptation. While trends like personalized treatment and digital health solutions hold promise, addressing challenges related to affordability, safety, and patient education remains crucial. Through sustained efforts and a patient-centered approach, the market can continue to evolve and positively impact the lives of millions affected by type 2 diabetes.

[wellhealthhub]

Diabetes Medicine: An In-depth Guide to Managing Diabetes

Looking for detailed information on diabetes medicine? This extensive article covers all aspects of effective diabetes management, including a wide range of treatments and medications. Gain insights from experts and real-life experiences. Introduction: Recognizing the Vitality of Diabetes Medicine Diabetes, a pervasive chronic condition afflicting millions worldwide, arises from impaired blood…

[cmibloggers]

In recent years, a breakthrough in diabetes management has emerged in the form of Glucagon-Like Peptide-1 (GLP-1) analogs. These innovative medications have revolutionized the treatment landscape by providing improved glycemic control and additional benefits for individuals with type 2 diabetes. 

Read More: https://cmibloggers.blogspot.com/2023/06/understanding-glucagon-like-peptide-1.html

[truemedmd]

New Weight Loss Anti-Diabetic Drugs Ozempic and GLP-1 Receptor Agonists

New Weight Loss Anti-Diabetic Drugs Ozempic and GLP-1 Receptor Agonists  by Jeffrey Dach MD What is the big deal about the new FDA approved weight loss anti-diabetic drugs such as Ozempic and other GLP-1 Receptor Agonists, liraglutide and semaglutide ? Maybe it is the celebrities going nuts on social media for these new weight loss drugs, thus creating massive demand and manufacturing shortages.…

[covid-safer-hotties]

Also preserved on our archive

by Kristen Monaco

Risk of new diabetes diagnosis was higher compared with non-COVID respiratory infections

Children and teens had an increased risk of being diagnosed with type 2 diabetes after COVID-19 infection, a retrospective cohort study of over 600,000 youth suggested.

Adolescents 10 to 19 years old had a 55% higher risk for a new diagnosis of type 2 diabetes 1 month after a COVID diagnosis compared with peers diagnosed with a non-COVID respiratory bug (risk ratio [RR] 1.55, 95% CI 1.28-1.89), reported Pauline Terebuh, MD, MPH, of Case Western Reserve University in Cleveland, Ohio, and colleagues.

The risk of a new type 2 diabetes diagnosis remained elevated at 3 months (RR 1.48, 95% CI 1.24-1.76) and 6 months (RR 1.58, 95% CI 1.35-1.85) after COVID infection, the group detailed in JAMA Network Openopens in a new tab or window.

"Youth diagnosed with diabetes will carry the burden of diabetes-related complications and increased medical costs for many years," Terebuh told MedPage Today. "All potential contributors to that trend are deserving of our attention, including COVID-19 and the increasing prevalence of obesity."

"COVID-19 is becoming endemic and strategies for mitigating its impact are extremely important," she said.

"SARS-CoV-2 may have the ability to selectively infect human pancreatic β cells, and if this triggers apoptosis, the ability of the pancreas to secrete insulin may be impaired," the researchers suggested. "Though T2D [type 2 diabetes] is usually considered to be a disease of insulin resistance rather than insulin lack, for newly diagnosed patients, the origin may not be entirely clear or confined to a single pathobiologic cause."

This wasn't the first time research suggested a link between COVID infection and diabetes in youth, but up until this point, most research focused on the relationship with type 1 diabetes. However, these studies have shown mixed results, with some studies indicating a linkopens in a new tab or window, and others dismissing the associationopens in a new tab or window.

Terebuh said while data have indicated an overall increase in new diagnosesopens in a new tab or window of type 2 diabetes among youth during the first year of the pandemic, this uptick has been a "worrisome trend" for decades.

"However, lots of things changed for youth during the pandemic from access to food to level of activity and stress," she pointed out. "The association with a COVID-19 diagnosis, per se, was not clear." To delve further into the topic, the researchers reviewed electronic health records on 613,602 patients from the TriNetX analytics platforms between January 2020 and December 2022. This included 306,801 patients diagnosed with COVID-19 (mean age 14.9 years, 52.8% female) and 306,801 with other respiratory infections (mean age 14.9 years, 52.6% female), after propensity score-matching.

Preexisting diabetes was grounds for exclusion.

In a subpopulation of adolescents with a BMI designating overweight or obesity (BMI in the 85th percentile for age or higher), a COVID diagnosis was tied with higher risks for developing type 2 diabetes at all three follow-up points compared with other respiratory infections: 1 month after: RR 2.07 (95% CI 1.12-3.83) 3 months after: RR 2.00 (95% CI 1.15-3.47) 6 months after: RR 2.27 (95% CI 1.38-3.75)

"New drugs for diabetes and obesity, such as GLP-1 receptor antagonists, provided they are safe, may have a role that should be studied," Terebuh suggested. Additionally, the researchers found the risk for developing type 2 diabetes was the highest for adolescents who were hospitalized within 1 month of a documented COVID infection: 1 month: RR 3.10 (95% CI 2.04-4.71) 3 months: RR 2.74 (95% CI 1.90-3.96) 6 months: RR 2.62 (95% CI 1.87-3.66)

Some diabetes diagnoses may have been preexisting and were discovered during the encounter for infection, the researchers pointed out. "Diagnoses made in the first month following infection may well represent preexisting disease, since the diagnosis of T2D is often confirmed by HbA1c measurements, which use mean blood glucose levels over the life span of the erythrocyte, or over 3 to 4 months," they wrote.

It will be important to test whether patients diagnosed soon after COVID-19 infection continue to meet diagnostic criteria for type 2 diabetes to separate patients who had diabetes from those who became hyperglycemic only during the metabolic stress of infection, they added.

Other limitations included potential confounders like vaccination status, socioeconomic status, BMI, or insulin resistance. In addition, patients with obesity and overweight weren't matched for obesity-specific treatments.

Study Link: jamanetwork.com/journals/jamanetworkopen/fullarticle/2824731

[mindblowingscience]

A drug commonly used to treat type 2 diabetes could also effectively protect against colorectal cancer (CRC), based on a new analysis by researchers in the US. The drug in question is a class of medications known as glucagon-like peptide-1 receptor agonists – more easily referred to as GLP-1 RAs. These medications, which include the widely-known 'wonder drug' sold under the commercial name Wegovy, have also previously been linked to weight loss and reducing the risk of cardiovascular problems.

Continue Reading.

[mitalipingale]

The GLP-1 Receptor Agonist Market in 2023 is US$ 14.44 billion, and is expected to reach US$ 23.58 billion by 2031 at a CAGR of 6.32%.